Symposium: Opportunities for MIDD for cell therapies
Are you interested in the future of clinical use of cell therapies? Attend the symposium on the 6th of November during ACoP, where Anna Mc Laughlin from Pharmetheus will chair and share her knowledge about 'Opportunities for Model-Informed-Drug-Development (MIDD) for cell therapies'.
Symposium session, November 6, 2.30 – 4.00 PM
Model-based optimization for (CAR-T) Cell Therapies – The current state of affairs and a way forward.
Chaired by
Anna Mc Laughlin, Dr. rer.nat, Consultant. Pharmetheus
Cassian Yee, Professor, University of Texas MD Anderson Cancer Center
Background
Cellular therapy, especially chimeric antigen receptor (CAR)-T cell therapy, has revolutionized the treatment of relapsed/refractory hematological malignancies. Several modeling and simulation (M&S) strategies, using a broad range of methodological approaches, have been developed to support both the rational development and clinical use of CAR-T cell therapy.
Session
This session aims at reflecting on the potential of existing CAR-T cell M&S strategies and highlighting the requirements from different stakeholders (industry, clinical/research, and regulatory) to further establish their use. Finally, as cell therapies beyond CAR-T cells evolve rapidly for oncology and other therapeutic areas, this session aims to provide an outlook on emerging cell therapy concepts and the associated challenges in translating existing CAR-T cell M&S strategies to new therapeutic modalities.
Topics & speakers
Aman P. Singh, Ph.D.
Associate Director, Takeda
Loretta Nastoupil, MD, Associate Professor.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center
Thibaud Derippe, Ph.D.
Clinical Pharmacologist & Pharmacometrician, AstraZeneca
Xiaofei Wang, Ph.D.
Scientist, FDA
Panel discussion